Both are FDA-approved for long-term use in chronic weight management
Brain metabolism in health, aging, and neurodegeneration
Research is still emerging, but one study done in humans found that while in the weight loss phase of taking a GLP-1 (compared to the maintenance phase), patients had a decreased preference for high-fat, savory foods, according to a 2024 review in the International Journal of Obesity
Experts note these symptoms can reflect underlying gastrointestinal changes linked to the drugs mechanism of action
Diets low in these nutrients, vegetarian or vegan lifestyles, high physical stress from intense exercise, and conditions like kidney disease or aging can reduce L-Carnitine production or increase its depletion, affecting energy and recovery
Not Approved Yet - More Research Needed Despite intriguing early evidence, GLP1 weightloss drugs are not currently approved to treat or prevent Alzheimers disease